Startseite>>Signaling Pathways>> GPCR/G protein>> Adrenergic Receptor>>YS-49

YS-49

Katalog-Nr.GC37954

YS-49 ist ein PI3K/Akt-Aktivator (ein nachgeschaltetes Ziel von RhoA), um die RhoA/PTEN-Aktivierung in den mit 3-Methylcholanthren behandelten Zellen zu reduzieren.

Products are for research use only. Not for human use. We do not sell to patients.

YS-49 Chemische Struktur

Cas No.: 132836-42-1

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
126,00 $
Auf Lager
10mg
114,00 $
Auf Lager
50mg
400,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

YS-49 inhibits Ang II-stimulated proliferation of VSMCs via induction of HO-1.IC50 value:Target: HO-1YS-49 is a novel positive inotropic isoquinoline compound. YS-49 has potential as a therapeutic strategy for the pathogenesis of Ang II-related vascular diseases such as hypertension and atherosclerosis, via the induction of HO-1 gene activity. YS-49 induced HO-1 protein production in a dose-and time-dependent manner in VSMCs. Treatment with YS-49 significantly and dose-dependently inhibited Ang II-induced VSMC proliferation, ROS production, and phosphorylation of JNK, but not P38 MAP kinase or ERK1/2.YS-49(32.8 microM) exhibited much stronger inhibitory effects on TXA(2) formation. The higher inhibitory potencies of YS-49 (IC(50): 3.3microM) than higenamine (IC(50): 140 microM) on AA induced rat platelet aggregation was presumed to be the result of low inhibitory effect of higenamine than YS-49 on TXA(2) production from AA. The oral administration of YS-49 (50 mg/kg) increased the recovery rates from the acute thrombotic challenge in mice and lowered the weight of thrombus formed inside the AV shunt tube in rats.

[1]. Lee YS, Kim CH, Yun-Choi HS,et al. Cardiovascular effect of a naphthylmethyl substituted tetrahydroisoquinoline, YS 49, in rat and rabbit. Life Sci. 1994;55(21):PL415-20. [2]. Kang YJ, Koo EB, Lee YS,et al. Prevention of the expression of inducible nitric oxide synthase by a novel positive inotropic agent, YS 49, in rat vascular smooth muscle and RAW 264.7 macrophages. Br J Pharmacol. 1999;128(2):357-64. [3]. Yun-Choi HS, Pyo MK, Park KM, et al. Antithrombotic effects of YS-49 and YS-51--1-naphthylmethyl analogs of higenamine . Thromb Res. 2001;104(4):249-55. [4]. Pyo MK, Yun-Choi HS, Chang KC, et al. Effects of two tetrahydroisoquinolines (YS-49 and YS-51) on experimental disseminated intravascular coagulation induced by lipopolysaccharide in rats. Arzneimittelforschung. 2004;54(11):705-10. [5]. Pyo MK, Kim JM, Jin JL,et al. Effects of higenamine and its 1-naphthyl analogs, YS-49 and YS-51, on platelet TXA2 synthesis and aggregation. Thromb Res. 2007;120(1):81-6. [6]. Sun JJ, Kim HJ, Seo HG, et al. YS49,1-(alpha-naphtylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline,regulates angiotensin II-stimulated ROS production, JNK phosphorylation and vascular smooth muscle cell proliferation via the induction of heme oxygenase-1. Life Sci. 2008;82(11-12):600-7.

Bewertungen

Review for YS-49

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for YS-49

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.